Abstract 6109
Background
Brachytherapy unit of the Catalan Institute of Oncology (ICO) is a referral centre on Brachytherapy treatments for Catalonia. A total of 700 treatments are performed per year, mainly in gynaecological, prostate and breast cancer. For the last 5 years, intraoperative brachytherapy has been promoted to be done in other centres, outside in the region. That implies that specialist professionals from our cancer centre go to operating rooms in different hospitals. The surgery process is done outside in the Paediatric hospital and the Brachytherapy treatment is realised in the cancer centre ICO. Aim: to describe nursing activities and roles to facilitate the Brachytherapy treatment done outside and in collaboration with other hospitals.
Methods
Descriptive study on cases done last year 2018 with patients outside ICO, most common type of treatments were sarcoma in paediatric tumours, patients with recurrence disease undergoing salvage after surgery or recurrence for breast cancer. Procedure: When a case arrived to the specialist they confirm indication and initiate the process; On the day of surgery, a medical and nurses team from the brachytherapy unit moves to hospital They perform the placement of internal applicators at the time of surgery. Later next 12-24h patient moves to brachytherapy unit to undergo the protocol of radiation. Once the brachytherapy treatment is finished, patient is discharged. The nursing staff of brachytherapy unit takes charge of plan care during treatment.
Results
Pediatric brachytherapy in oncological patient: experience of collaboration of 5 years with 10 patients treated. A total of 53 breast brachytherapy has been done intraoperative: consolidated collaboration, generates around 3 monthly patients from different medical centers. A total of 10 cases done for salvage brachytherapy in patients with recurrence after surgery.
Conclusions
Intraoperative brachytherapy improves the patient’s accessibility to highly specialized treatments. The procedure and development of this treatment in different hospitals improves results in some tumours, reduces the overall time of treatment. Nursing staff has knowledge and skills for the management and care of this patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3212 - Multigene panel testing results for hereditary breast cancer in 1325 individuals: implications for gene selection and considerations for guidelines.
Presenter: Georgios Tsaousis
Session: Poster Display session 3
Resources:
Abstract
2591 - PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors
Presenter: Julia Quintanilha
Session: Poster Display session 3
Resources:
Abstract
4377 - ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): a retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials.
Presenter: Nuria Chic
Session: Poster Display session 3
Resources:
Abstract
3439 - Early on-treatment vs pre-treatment tumor transcriptomes as predictors of response to neoadjuvant therapy for HER2-positive inflammatory breast cancer
Presenter: Sonia Pernas
Session: Poster Display session 3
Resources:
Abstract
2512 - AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC)
Presenter: Claudia Cardone
Session: Poster Display session 3
Resources:
Abstract
4061 - Prevalence of EGFR mutations and its correlation with Egyptian patients’ human kinetics (PEEK Study)
Presenter: Adel Ibrahim
Session: Poster Display session 3
Resources:
Abstract
2547 - Evaluation of tumor microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)
Presenter: Sergio Rutella
Session: Poster Display session 3
Resources:
Abstract
4671 - Clinicopathological and molecular criteria assessment for the screening of hypermutated proficient mismatch repair (pMMR) colorectal cancers (CRC) with exonucleasic domain POLE (edPOLE) mutations (mt).
Presenter: Benoit Rousseau
Session: Poster Display session 3
Resources:
Abstract
3862 - Tumor mutation burden and microsatellite instability in colorectal cancer
Presenter: Francesca Fenizia
Session: Poster Display session 3
Resources:
Abstract
4614 - Predictors of Response to Checkpoint Inhibitors in Naïve and Ipilimumab-Refractory Melanoma
Presenter: Domenico Mallardo
Session: Poster Display session 3
Resources:
Abstract